Atherosclerosis
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our results establish a role for PPARgamma in the regulation of EC gene expression, with important implications for the clinical links between obesity and atherosclerosis.
|
10073956 |
1999 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The role of oxidized low-density lipoprotein in the activation of peroxisome proliferator-activated receptor gamma: implications for atherosclerosis.
|
10101923 |
1999 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Pharmacological activation of PPARgamma expressed in VSMCs inhibits their proliferation and migration, potentially limiting restenosis and atherosclerosis.
|
10725292 |
2000 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We report here that the PPARgamma-specific agonists rosiglitazone and GW7845 strongly inhibited the development of atherosclerosis in LDL receptor-deficient male mice, despite increased expression of the CD36 scavenger receptor in the arterial wall.
|
10953027 |
2000 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Recent studies showed that PPARgamma is also expressed in monocytes/macrophages and is suggested to be involved in atherosclerosis.
|
11500181 |
2001 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
This issue is important because thiazolidinediones, which are ligands for PPARgamma, have recently been approved for the treatment of type 2 diabetes, a state of accelerated atherosclerosis.
|
11231915 |
2001 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor involved in such cellular processes as adipogenesis, inflammation, atherosclerosis, cell cycle control, apoptosis, and carcinogenesis.
|
12364466 |
2002 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results add to the concern that the clinical use of insulin-sensitizing PPARgamma agonists (i.e. thiazolidinediones) to treat Type 2 Diabetes could exacerbate atherosclerosis, and highlight the need for clinical trials that address this issue.
|
12417276 |
2002 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Although activation of PPARgamma appears to have beneficial effects on atherosclerosis and heart failure, it is still largely uncertain whether PPARgamma ligands prevent the development of cardiovascular diseases.
|
12861348 |
2003 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator activated receptor gamma (PPARgamma) modulates atherosclerosis by its anti-inflammatory and anti-protease activity.
|
16311343 |
2005 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications.
|
16259527 |
2005 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, as more PPARgamma targeted pathways are revealed such as bone homeostasis, atherosclerosis and longevity, it is most certain that the PPARgamma thrifty gene hypothesis will evolve to incorporate these.
|
15667578 |
2005 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
LHGDN |
In conclusion, stimulation of CYP27A1 by PPARgamma may represent a key previously unrecognized mechanism by which PPARgamma protects against atherosclerosis.
|
15533057 |
2005 |
Atherosclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Since a crosstalk between AGE and angiotensin II (Ang II) has been proposed in the pathogenesis of accelerated atherosclerosis in diabetes, we examined here whether and how telmisartan, a unique Ang II type 1 receptor blocker (ARB) with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity, could inhibit AGE-induced CRP expression in a human hepatoma cell line, Hep3B cells.
|
17004092 |
2006 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis.
|
17261671 |
2007 |
Atherosclerosis
|
0.500 |
Therapeutic
|
disease |
CTD_human |
[Rosiglitazone enhances the anti-atherosclerotic effects of peroxisome proliferator-activated receptor gamma1 gene transfer in apolipoprotein-knock out mice].
|
18269830 |
2007 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPARgamma) is a transcription factor implicated in the expression of proinflammatory cytokines in atheroma-associated cells, and the expression of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-alpha) and matrix metalloproteinases (MMPs), represents a critical step in atherogenesis and atherosclerosis.
|
17892998 |
2007 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor that has been suggested to play protective roles in the pathogenesis of diseases that are characterized by chronic inflammation, such as atherosclerosis.
|
18308193 |
2008 |
Atherosclerosis
|
0.500 |
PosttranslationalModification
|
disease |
LHGDN |
Homocysteine-mediated PPARalpha,gamma DNA methylation and its potential pathogenic mechanism in monocytes.
|
18004978 |
2008 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
BACKGROUND Peroxisome proliferator-activated receptor gamma (PPARgamma) is involved mainly in adipocyte differentiation and has been suggested to play an important role in the pathogenesis of insulin resistance (IR) and atherosclerosis.
|
18362424 |
2008 |
Atherosclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The interaction result for S(I) was replicated by the Insulin Resistance Atherosclerosis Family Study (P = 0.018) in their San Antonio sample (n = 484) where subjects with at least one PPARG2 Ala allele and homozygous for the HNF4A rs2144908 A allele had a 29% higher S(I) compared with individuals with at least one G allele.
|
18162503 |
2008 |
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Together, these results indicate that the stimulation of SR-B1 expression in the liver is mediated in part by activation of the PPAR-gamma and RXR, and raise the possibility that this stimulation using thiazolidinediones conditions provides a protective mechanism for accelerated atherosclerosis in diabetes mellitus.
|
19156545 |
2009 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
For the first time we demonstrate that CRP modulates PPAR-gamma and its effector genes and reinforces the mechanistic link of CRP as a possible mediator in atherosclerosis and also advocate atorvastatin as a therapeutic modality.
|
20682172 |
2010 |
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
|
20508203 |
2010 |